Dementia-related psychosis readout could lead to label expansion for Acadia's Nuplazid

A new Phase III readout could speed Acadia's timeline to a potential regulatory submission of pimavanserin to treat dementia-related psychosis, an indication that afflicts a much larger population than the one for which the molecule is already approved as Nuplazid.

Acadia Therapeutics

Read the full 414 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE